Pharma Ignite

Pharma Ignite is the new-look marketing insights division of Citeline.

[Pharma Ignite @PharmaIgnite]

🚨 Entries are now OPEN for the Scrip Awards 2026!

From groundbreaking therapies to standout partnerships and cutting-edge research, this is your opportunity to showcase your achievements on a global stage.
Enter now 👉 https://t.co/zscAmWvBcd

[Pharma Ignite @PharmaIgnite]

What does it actually take to deliver a vaccine manufacturing project?
New facilities. New tech. Full validation. Regulatory approval. All in under two years.
A grounded look from the team behind it: https://t.co/g8u4E8wpgX

[Pharma Ignite @PharmaIgnite]

Clinical evidence isn’t always enough.
This webinar by Lucid Group explores how pharma teams can better understand stakeholder behaviour, societal dynamics, and ecosystem complexity before launch strategy begins.
Register now: https://t.co/SCN8otJWSB

[Pharma Ignite @PharmaIgnite]

How can integrated ddPCR, NGS & RNA-seq strengthen infectious disease trials?

Join @Citeline & hVIVO on April 29 to explore practical molecular workflows supporting pathogen detection, resistance tracking & host-response discovery.
Register: https://t.co/4MkV6GPiC3

[Pharma Ignite @PharmaIgnite]

With patents expiring through 2040, regulatory shifts and advanced modalities are reshaping development strategy.
Explore the latest white paper: https://t.co/KCszz7KUZj

[Pharma Ignite @PharmaIgnite]

Last chance to register! Taking a drug from discovery to first-in-human is a defining milestone for startups.
Join hVIVO’s experts on March 18 for practical insights on IND readiness, early planning and risk reduction.

👉 Register here: https://t.co/awMJvLUDfQ

[Pharma Ignite @PharmaIgnite]

Early-phase oncology decisions can’t wait for perfect data.
This webinar explores how teams interpret emerging signals, manage uncertainty, and move forward responsibly during study conduct.

Register now: https://t.co/9WK1Dcvgzj

[Pharma Ignite @PharmaIgnite]

Integration across clinical, supply, and manufacturing may be the missing link. Explore how connected execution models help AI deliver faster, more reliable outcomes across the lifecycle.

Read now: https://t.co/TwcW3sVICJ

[Pharma Ignite @PharmaIgnite]

Excipient purity and supply resilience are now central to biologics development.
Explore how evolving quality expectations and DFE Pharma’s scientific and manufacturing strengths support more reliable, higher-performing formulations: https://t.co/BtTs4taJLB

[Pharma Ignite @PharmaIgnite]

Last chance to register! This webinar explores how MBMA and QSP can support earlier Phase 3 go/no-go decisions, align evidence with payer expectations, and reduce reimbursement uncertainty.

Register now: https://t.co/dcCzmegzhb

[Pharma Ignite @PharmaIgnite]

As trials grow more complex, execution pressure is changing how evidence is produced. New insights explore why participation, retention, and real-time data capture are becoming central to trial performance, and what this signals for 2026.

Read more: https://t.co/ZMMBvYhqfX

[Pharma Ignite @PharmaIgnite]

Materiovigilance is undergoing a fundamental shift.

New IQVIA research explores how regulatory complexity, technology change, and operational pressure are reshaping safety oversight.

Read The State of Materiovigilance 2025: https://t.co/lpRsIgp9ZB

[Pharma Ignite @PharmaIgnite]

Digital health technologies are changing how neurodegenerative disease trials are designed, enabling continuous data capture, and new digital endpoints.

Explore how evolving global guidance is shaping the future of neuroscience trials: https://t.co/EhguBDWAOG

[Pharma Ignite @PharmaIgnite]

How do nonclinical safety and PK/PD data shape early CNS drug development?

This webinar explores practical approaches to CNS risk assessment and clinical decision-making for novel neurotherapeutics: https://t.co/UQgVCxVNZy

[Pharma Ignite @PharmaIgnite]

Live Webinar with Citeline and hVIVO:
Taking a drug from discovery to first-in-human is a defining milestone for startups.
Join hVIVO’s experts on March 18 for practical insights on IND readiness, early planning and risk reduction.
Register: https://t.co/13A1UqybbE

[Pharma Ignite @PharmaIgnite]

Early reimbursement decisions matter.
This webinar explores how MBMA and QSP can help HEOR teams inform Phase 3 go/no-go decisions, align evidence with payer expectations, and reduce uncertainty earlier.

Register now: https://t.co/kBlqNtp4wY

[Pharma Ignite @PharmaIgnite]

In pediatric rare disease trials, every patient—and every data point matters. Learn how ethical design, operational strategy, and modeling approaches are reshaping early-phase development in this expert interview: https://t.co/0pRPwYs3gP

[Pharma Ignite @PharmaIgnite]

Tap into top trends in real-world evidence (RWE) as @IQVIA_global presents 6 key takeaways and lessons learned from case studies for successful regulatory engagements: https://t.co/D6jMbVhITq

[Pharma Ignite @PharmaIgnite]

Explore best practices for scientific communications strategies and capture the learnings from two case studies that used @IQVIA_global's Share of Scientific Voice™ (SoSV) tool to drive launch success: https://t.co/8KLS99mq2t

[Pharma Ignite @PharmaIgnite]

The future of oncology R&D: Experts from @ICONplc, Johnson & Johnson, NextPoint Therapeutics and more discuss next-gen modalities, precision trials, AI’s impact, and the critical role of collaboration with regulators and payers: https://t.co/XOPxTvyOul